The outcomes of concomitant hypofractionated simultaneous integrated boost intensity-modulated radiotherapy with temozolomide for newly diagnosed high grade gliomas

Abstract

Author(s): Rasha Abd El-Ghany Khedr, Mohamed Fathy Sheta, Walid Elmorsy

Purpose: Despite the multidisciplinary approach, within 2 cm of the primary site, 77% of Glioblastoma Multiforme (GBM) will recur. Thus, higher radiation dose seems reasonable to improve local control. We reported the preliminary results of the treatment with concomitant hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy (SIB-IMRT) plus Temozolomide (TMZ) followed by adjuvant TMZ therapy in patients with newly diagnosed GBM to determine the safety, tolerability, and efficacy. Patients and Methods: Between January 2018 and February 2020, a total of 27 patients over the age of 18 years with newly diagnosed, histologically confirmed GBM were assigned to receive oral TMZ (75 mg/m2/d × 7 d/wk for 6 weeks, from the first to the last day of RT) with fractionated RT (2.4 Gy, 2.2 Gy, and 2.0 Gy per fraction to PGTV, PCTV high risk, and PCTV low risk, 5 d/wk, for a total of 64.8 Gy, 59.4 Gy and 54 Gy, respectively) followed by TMZ monotherapy (150 mg/m2/d to 200 mg/m2/d × 5 days, every 28 days for six cycles) at Clinical Oncology Department, Faculty of Medicine, Tanta University Hospital. The primary end point was overall survival; secondary end points were progression-free survival, safety and tolerability. The date of this analysis is February 2021. Results: At a median follow-up period of 20 months (range; 5-30 months), the median Progression-Free Survival (PFS) for all patients with GBM was 14 months, and the 2-year PFS rate was 19.2%. The median Overall Survival (OS) was 20 months and the 2-year OS rate was 40.8%. The mean age was 50.2 years (standard deviation ± 9.7284), and 44.4% of patients had undergone biopsy only. There was no mortality caused by drug toxicity. Patients younger than 50 years old and patients who underwent debulking surgery had the best survival outcome. Conclusion: The addition of TMZ to hypofractionated SIB-IMRT followed by adjuvant TMZ was well tolerated and has shown promising activity in the treatment of newly diagnosed GBM. Further investigation is warranted.

Share this article

Editors List

  • S.SREEDHAR

    Submitted PhD thesis in Biotechnology at GITAM University, Vizag.

  • Yousef Alomi

    Yousef Alomi
    The Past Head, General Administration of Pharmaceutical Care at Ministry of Health,
    Saudi Arabia Critical Care/TPN
    Clinical Pharmacist Ministry of Health,
    Riyadh, Saudi Arabia.

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

Google Scholar citation report
Citations : 61

Onkologia i Radioterapia received 61 citations as per Google Scholar report

Onkologia i Radioterapia peer review process verified at publons
Indexed In
  • Scimago
  • SCOPUS
  • MIAR
  • Euro Pub
  • Google Scholar
  • Medical Project Poland
  • PUBMED
  • Cancer Index
  • Gdansk University of Technology, Ministry Points 20